Kris Vaddi, Ph.D. is a drug discovery scientist and the founder of cancer focused startup companies Orsenix and Prelude Therapeutics, and a not-for-profit venture Sidus Healthcare. Prior to his new ventures, Kris had a 14-year career at Incyte starting as a founding scientist and an executive director in 2002 and most recently as a group vice president in 2016. Kris initiated and championed JAK research programs at Incyte that led to the discovery, development and approval of Jakafi® (ruxolotinib) for Myelofibrosis and Polycythemia Vera and Olumiant® (Baricitinib) for rheumatoid arthritis. Kris received his Doctorate in Veterinary Medicine from APAU in India and his Ph.D. from University of Florida.